Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Dooley

Showing results (231-240 of 263) with videos related to

Pageof 27
Sort By:
Medicine and Science in Sports and Exercise|November 18, 2025
Associations of Accelerometer-Determined Sedentary and Physical Activity Behaviors with Heart Failure Biomarkers During Midlife: CARDIA StudyKelley Pettee Gabriel, Bjoern Hornikel, Erin E Dooley, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 2, 2024
Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral TherapyAhizechukwu C Eke, Sean S Brummel, Muktar H Aliyu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2022
Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS TrialMandar S Paradkar, Bella Devaleenal D, Tisungane Mvalo, et al.
Biorxiv : the Preprint Server for Biology|February 9, 2026
Bidirectional fibrogenic cross-talk revealed in a human iPSC-derived epithelial-mesenchymal co-culture model of pulmonary fibrosisAndrea B Alber, George Kwong, Vishal K Gupta, et al.
Open Forum Infectious Diseases|April 22, 2021
Diabetes Mellitus and Tuberculosis Treatment Outcomes in Pune, IndiaVidya Mave, Sanjay Gaikwad, Madhusudan Barthwal, et al.
Journal of Physical Activity & Health|December 6, 2025
Results From the 2024 United States Report Card on Physical Activity for Children and YouthJordan A Carlson, Mallory Moon, Chelsea Steel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2024
Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for TuberculosisHuy X Ngo, Ava Y Xu, Gustavo E Velásquez, et al.
Emerging Infectious Diseases|March 2, 2025
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with DiabetesEkaterina V Kurbatova, William C Whitworth, Lakshmi Praveena Peddareddy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
American Journal of Respiratory and Critical Care Medicine|July 16, 2024
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical TrialAva Y Xu, Gustavo E Velásquez, Nan Zhang, et al.
Pageof 27

Showing results (231-240 of 263) with videos related to

Sort By:
Pageof 27
Medicine and Science in Sports and Exercise|November 18, 2025
Associations of Accelerometer-Determined Sedentary and Physical Activity Behaviors with Heart Failure Biomarkers During Midlife: CARDIA StudyKelley Pettee Gabriel, Bjoern Hornikel, Erin E Dooley, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 2, 2024
Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral TherapyAhizechukwu C Eke, Sean S Brummel, Muktar H Aliyu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2022
Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS TrialMandar S Paradkar, Bella Devaleenal D, Tisungane Mvalo, et al.
Biorxiv : the Preprint Server for Biology|February 9, 2026
Bidirectional fibrogenic cross-talk revealed in a human iPSC-derived epithelial-mesenchymal co-culture model of pulmonary fibrosisAndrea B Alber, George Kwong, Vishal K Gupta, et al.
Open Forum Infectious Diseases|April 22, 2021
Diabetes Mellitus and Tuberculosis Treatment Outcomes in Pune, IndiaVidya Mave, Sanjay Gaikwad, Madhusudan Barthwal, et al.
Journal of Physical Activity & Health|December 6, 2025
Results From the 2024 United States Report Card on Physical Activity for Children and YouthJordan A Carlson, Mallory Moon, Chelsea Steel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2024
Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for TuberculosisHuy X Ngo, Ava Y Xu, Gustavo E Velásquez, et al.
Emerging Infectious Diseases|March 2, 2025
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with DiabetesEkaterina V Kurbatova, William C Whitworth, Lakshmi Praveena Peddareddy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
American Journal of Respiratory and Critical Care Medicine|July 16, 2024
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical TrialAva Y Xu, Gustavo E Velásquez, Nan Zhang, et al.
Pageof 27